Skip to content
APREAprea Therapeutics, Inc.

Earnings

When Aprea Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

33 quarters. Sep 30, 2018 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

Mar 15, before the open

Mon, Mar 15, 2027in 117 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 15 – 31

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$2.46M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$4.81MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, before the openThe release+5.8%by the close of Nov 4
    Revenue
    —
    —
    Net income
    -$4.81M
    N/M
    EPS
    -$0.09
    N/M
  2. Q2 2026Aug 12, 2026, before the openThe release+3.0%by the close of Aug 12
    Revenue
    —
    —
    Net income
    -$3.59M
    N/M
    EPS
    -$0.07
    N/M
  3. Q1 2026May 13, 2026, before the openThe release9.2%by the close of May 13
    Revenue
    —
    —
    Net income
    -$3.29M
    N/M
    EPS
    -$0.22
    N/M
  4. Q4 2025Mar 16, 2026, before the openThe release+2.5%by the close of Mar 16
    Revenue
    —
    —
    Net income
    -$2.46M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · pre-marketNov 4, 202635 d10-Q——-$0.09+5.8%
Q2 2026Jun 30, 2026Aug 12, 2026 · pre-marketAug 12, 202643 d10-Q——-$0.07+3.0%
Q1 2026Mar 31, 2026May 13, 2026 · pre-marketMay 13, 202643 d10-Q——-$0.229.2%
FY 2025
Q4 2025derivedDec 31, 2025Mar 16, 2026 · pre-marketMar 16, 202675 d10-K———+2.5%
Q3 2025Sep 30, 2025Nov 12, 2025 · pre-marketNov 12, 202543 d10-Q——-$0.478.6%
Q2 2025Jun 30, 2025Aug 12, 2025 · pre-marketAug 12, 202543 d10-Q——-$0.530.6%
Q1 2025Mar 31, 2025May 14, 2025 · pre-marketMay 14, 202544 d10-Q——-$0.660.0%
FY 2024
Q4 2024derivedDec 31, 2024Mar 25, 2025 · pre-marketMar 25, 202584 d10-K———5.2%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q——-$0.647.0%
Q2 2024Jun 30, 2024Aug 12, 2024 · pre-marketAug 12, 202443 d10-Q——-$0.58—
Q1 2024Mar 31, 2024May 14, 2024 · pre-marketMay 14, 202444 d10-Q——-$0.67+9.4%
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026122405
10-QAug 12, 2026094544
10-QMay 13, 2026059743
10-KMar 16, 2026028068
10-QNov 12, 2025109867
10-QAug 12, 2025011152
10-QMay 14, 2025007667
10-KMar 25, 2025003588
10-QNov 7, 2024014767
10-QAug 12, 2024011806

Provenance

ProvenanceData status and checks

Aprea Therapeutics, Inc. · CIK 1781983 · Engraved from SEC EDGAR